ADL Amdl,

TUSTIN, Calif., Jan. 22 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, said today the South Korean company MyGene, Inc., has announced it has won approval from its government to market AMDL's unique DR-70(R) cancer diagnostic test kit in that nation. MyGene is affiliated with approximately 100 medical centers in South Korea, which has a population of close to 50 million people, and currently markets a unique test for human papilloma virus for cervical cancer, as well as BRC1 and BRC2 for breast cancer. "MyGene is well respected throughout the South Korean medical community," said Gary L. Dreher, AMDL CEO. "South Korea is a nation of more than 50 million people and we are pleased that MyGene will be distributing our flagship product in this important southeastern Asian country." DR-70(R), a non-invasive blood test, has shown in clinical trials conducted in Germany, Canada, Taiwan, China and Turkey to be able to detect the presence of one or more cancers 84 percent of the time. These cancers include lung, colon, breast, stomach, liver, cervical and malignant lymphoma. "We are very optimistic about the acceptance of this excellent product in South Korea, a nation where preventative medicine is very important. We are confident that South Koreans will view this as a great assistance in improving the quality of life of its population," said Dr. Dukjoo Lee, President of MyGene. "We have applied for National Health Insurance reimbursement for DR-70(R) and we are optimistic about that approval." AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 14 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. More information about AMDL and its additional products can be obtained at http://www.amdl.com/. About MyGene: MyGene Inc., headquartered in Seoul, Korea, is a major developer and distributor of life science research products based on proprietary technologies in the area of genomics and proteomics. One of the Company's important goals is to distribute state of the art technologies of human cancer detection kits such as AMDL's DR-70(R) through its well stabilized market channel in Korea. MyGene products are designed to aid in the discovery and development of diagnostics for human healthcare and animal as well. MyGene's first products are Oligo chip based lab-on-a-chip tools for use in identifying and investigating the roles of genes, gene mutations and proteins. Oligo chip based systems are capable of performing multiplexed assays involving DNA, RNA, protein, peptides or molecules. More information about MyGene can be obtained at http://english.mygene.net/ . About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its additional products can be obtained at http://www.amdl.com/. Forward-Looking Statements Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. CONTACT: AMDL, Inc. Gary L. Dreher President & CEO P# (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/ http://english.mygene.net/

Copyright